Xenon reports Phase 2 XEN1101 MDD trial misses primary endpoint but hits secondary measures

Xenon Pharmaceuticals Inc.

MADRS at week 6: placebo reduction 13.90; XEN1101 20 mg reduction 16.94 (p=0.135), not statistically significant.
HAM-D17 (p=0.042) and anhedonia SHAPS (p=0.046) secondary endpoints met statistical significance for 20 mg.
Early onset: MADRS at week 1 showed significance for 20 mg (p=0.047); CGI-I also significant (p=0.004).
XEN1101 well tolerated; no SAEs in active arms; common TEAEs: dizziness (17.9%), somnolence (10.7%), headache (8.9%).
Company exploring future MDD development; XEN1101 also in Phase 3 epilepsy with no titration required.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.